Tirzepatide

Product Description

Tirzepatide is an FDA-approved 39-amino acid peptide that acts on both GIP and GLP-1 receptors simultaneously. Marketed as Mounjaro (diabetes) and Zepbound (weight loss), it has shown remarkable efficacy in clinical trials, with participants losing up to 22% of their body weight.